Utah Medical Products
UTMD
92 hedge funds and large institutions have $241M invested in Utah Medical Products in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 32 increasing their positions, 33 reducing their positions, and 7 closing their positions.
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
5% more capital invested
Capital invested by funds: $229M → $241M (+$12.5M)
5% more funds holding
Funds holding: 88 → 92 (+4)
0.29% less ownership
Funds ownership: 73.28% → 72.99% (-0.29%)
3% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.07M |
| 2 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$1.88M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$989K |
| 4 |
PC
Port Capital
Chicago,
Illinois
|
+$714K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$557K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lazard Asset Management
New York
|
-$2.82M |
| 2 |
State Street
Boston,
Massachusetts
|
-$2.02M |
| 3 |
AA
Ancora Advisors
Cleveland,
Ohio
|
-$1.19M |
| 4 |
Morgan Stanley
New York
|
-$1.03M |
| 5 |
BlackRock
New York
|
-$1.02M |
UTMD Hedge Fund Activity: Q1 2019 in Review
92 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Utah Medical Products (UTMD) for Q1 2019, worth a combined $241M — up 5.5% from $229M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new UTMD positions and 7 closed out — a net gain of 4 holders — while 32 added to existing stakes and 33 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $2.07M. The largest seller was Lazard Asset Management, cutting an estimated $2.82M.
- 92 institutional investors held Utah Medical Products (UTMD) as of Q1 2019, up from 88 in Q4 2018.
- Funds reported $241M of Utah Medical Products stock for Q1 2019, up 5.5% quarter-over-quarter.
- 11 funds opened new Utah Medical Products positions in Q1 2019 and 7 closed out, a net change of +4 holders.
- The largest Utah Medical Products buyer in Q1 2019 was T. Rowe Price Associates, an estimated $2.07M added.
- The largest Utah Medical Products seller in Q1 2019 was Lazard Asset Management, an estimated $2.82M sold.
Based on aggregated 13F filings for Q1 2019.